. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 May 13;19(9):593–597. doi: 10.1016/j.clml.2019.05.009

Table 2:

Baseline clinical and laboratory characteristics for myelofibrosis patients who had echocardiograms. Patients are divided into with and without PH cohorts.

	MF without PH n=11 (44%)	MF with Group 5 PH n=14 (56%)	P-value
Age	66	70.5	0.11

Sex
Male	8	5	0.07
Female	3	9

Primary MF	8	8	0.42

WBC	4.6	8.7	0.13

Hgb	9.8	9.2	0.91

Platelets	121	261	0.35

Constitutional Symptoms^a	4(40)% (n=10)	1(7.7%) (n=13)	0.06

Transfusion Requirement	3	3	0.71

Circulating Blast Cells ≥1%^a	2(20%) (n=10)	5(36%) (n=14)	0.4

JAK 2 Status^b	5(63)% (n=8)	4(36%) (n=11)	0.26

^a-

Sample size (n) limited by incomplete data entry in the electronic medical record

^b-

Sample size limited based on availability of ordered test and/or results